What are the long term risks of remicade treatment?

What side effects do patients report after years on Remicade?
Infliximab (Remicade) can trigger new or reactivated infections, especially tuberculosis and hepatitis B, that may appear months or years after treatment begins. Regular skin testing or blood work is required before and during therapy to catch these infections early. Patients also face a small but documented rise in lymphoma and other cancers, with the risk increasing the longer treatment continues.

How long can Remicade be used safely?
No fixed upper limit exists. Many patients stay on the drug for five to ten years or longer when benefits outweigh risks. Doctors usually reassess the need for continued therapy every one to two years and consider dose reductions or drug holidays if disease activity is low.

Can Remicade damage the heart or nervous system?
Rare cases of heart failure have been linked to infliximab, leading doctors to avoid the drug in patients with moderate to severe heart problems. Demyelinating disorders such as multiple sclerosis have also surfaced during treatment, prompting immediate discontinuation if neurological symptoms develop.

Why do some people develop resistance to Remicade?
Over time the immune system can form antibodies against infliximab, reducing its effectiveness. Loss of response often appears after one to three years and may require higher doses, shorter intervals, or a switch to another biologic.

What happens if treatment stops?
Disease flare is common once infliximab is withdrawn, especially in Crohn’s disease and rheumatoid arthritis. Restarting the drug after a long break raises the chance of infusion reactions and antibody formation, so doctors often taper or overlap with another agent instead of abrupt cessation.

How does Remicade compare with Humira or Entyvio for long-term safety?
Remicade and Humira share similar infection and cancer warnings, though Humira allows at-home injections and may carry a slightly lower rate of infusion reactions. Entyvio targets gut-specific inflammation and shows lower systemic infection risk, but it works more slowly in some patients. Choice often depends on prior response, cost, and insurance coverage.

When do patents for Remicade expire, and what does that mean for biosimilars?
The main U.S. patent for Remicade expired in 2018, yet additional manufacturing and dosing patents have delayed full biosimilar competition. Several infliximab biosimilars are now available, usually at 20–30 % lower cost, and real-world data so far show comparable long-term safety profiles.